Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Consumer groups, unions oppose fix for planned merger of AbbVie and Allergan

share with twitter share with LinkedIn share with facebook
share via e-mail
02/18/2020 | 02:56pm EST
The Allergan logo is seen in this photo illustration

A group of unions and consumer groups wrote to U.S. antitrust enforcers on Tuesday to oppose a proposed remedy that could lead to U.S. approval for AbbVie Inc's planned purchase of Allergan Plc.

In its letter to the Federal Trade Commission, which is reviewing the merger to ensure it is legal, the groups argued that a plan for the companies to divest Allergan's brazikumab, which is being developed to treat ulcerative colitis and Crohn's disease, was inadequate to resolve antitrust concerns raised by the planned deal.

AbbVie did not immediately respond to a request for comment.

The groups argued that the proposed buyer, AstraZeneca, appeared to have little incentive to bring the drug to market and that rebates offered by AbbVie for its Skyrizi drug would slow brazikumab's success in the market since both drugs treat similar ailments.

"We are skeptical that the divestiture to AstraZeneca of Allergan?s brazikumab, a drug in development, can adequately address the anticompetitive effects of the merger," said the letter, which was signed by the American Federation of Teachers, Families USA, U.S. PIRG Education Fund, Service Employees International Union (SEIU), American Federation of State, County, & Municipal Employees (AFSCME) and 12 other groups.

The $63 billion deal, which is expected to close this quarter, was approved by the European Union in January.

The deal was initially announced in June as a way for AbbVie to win control over the lucrative wrinkle treatment Botox and buy time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection. AbbVie Chief Executive Richard Gonzalez said at the time that the company was able to buy Allergan because of the cash that Humira generates.

(Reporting by Diane Bartz; Editing by Dan Grebler)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA PLC
02/18Consumer groups, unions oppose fix for planned merger of AbbVie and Allergan
02/17ASTRAZENECA PLC : - Full-year and Q4 2019 results
02/14Health Care Flat Amid Mixed Earnings Season -- Health Care Roundup
02/14EUROPE : European shares settle below record highs
02/14FTSE 100 ends week lower after week AstraZeneca, RBS results
02/14NEWS HIGHLIGHTS : Top Company News of the Day
02/14GLOBAL MARKETS LIVE: Facebook ready to pay more taxes, Amazon gets JEDI suspe..
02/14AstraZeneca's CEO reaffirms 2021 targets
02/14AstraZeneca braces for coronavirus hit, but no impact so far
02/14NEWS HIGHLIGHTS : Top Company News of the Day
More news
Financials (USD)
Sales 2020 26 954 M
EBIT 2020 7 380 M
Net income 2020 2 965 M
Debt 2020 13 046 M
Yield 2020 2,90%
P/E ratio 2020 39,3x
P/E ratio 2021 25,9x
EV / Sales2020 5,24x
EV / Sales2021 4,69x
Capitalization 128 B
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 106,47  $
Last Close Price 97,77  $
Spread / Highest target 41,7%
Spread / Average Target 8,90%
Spread / Lowest Target -23,7%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Marcus Wallenberg Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-1.13%128 554
JOHNSON & JOHNSON2.92%392 517
ROCHE HOLDING AG8.47%299 201
NOVARTIS4.05%220 283
MERCK AND COMPANY-9.33%209 942
PFIZER-6.81%200 999